Study of TQB2029 for multiple myeloma patients
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new injectable drug, TQB2029, for people with multiple myeloma. It aims to see if the drug is safe and effective, and may be an option if you have measurable disease and are in relatively good health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old
- You have multiple myeloma that is measurable (for example, by blood or urine tests)
- You are in generally good health (able to care for yourself and up and about more than half of your waking hours)
- You are willing to use effective birth control during the study
- You have not had certain other cancer treatments (like targeted therapy or immunotherapy) within the past few weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injectable treatment for people with multiple myeloma that has come back or not responded to previous therapies. It aims to see if the drug is safe and effective.
This study tests a new drug called TQB2934 for patients whose multiple myeloma (a blood cancer) has returned or stopped responding to previous treatments. The goal is to see if this injection can help control the disease.
This study tests a new biosimilar drug called QL2109, which is similar to daratumumab (a treatment for multiple myeloma). Healthy men aged 18-50 will receive one dose to see how the body processes it and if it causes any side effects.
This early-stage trial tests a new drug called QI-019B in patients whose multiple myeloma (a blood cancer) has stopped responding to standard treatments. The study checks if QI-019B is safe and whether it helps slow or stop the cancer's growth.
This trial tests a new drug, TQB2922, for people with advanced cancers that have not responded to standard treatments. The goal is to see if it is safe and how it affects the cancer.
This phase 1 trial tests an experimental drug called TQB2252 for people with advanced cancers that have not responded to standard treatments. The drug blocks a protein called LAG3 to help the immune system attack cancer cells.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.